Table 2. Levels of circulating cytokines and MMPs with a significant difference in NSCLC and COPD patients.
| Cytokine/MMP | NSCLC median | COPD median | P-value |
|---|---|---|---|
| CCL1/I-309 | 77 | 89 | 0.041 |
| MIP-3a (CCL20) | 24 | 17 | 0.036 |
| MIP-3b (CCL19) | 919 | 606 | 0.029 |
| TARC (CCL17) | 400 | 253 | 0.011a |
| Eotaxin (CCL11) | 63 | 72 | 0.037 |
| Gro-b (CXCL2) | 878 | 514 | <0.001a |
| CXCL13 | 54 | 36 | 0.000a |
| Fractalkine (CX3CL1) | 254 | 212 | 0.025 |
| IL-1ra | 434 | 1079 | <0.001a |
| IL-6 | 27 | 16 | 0.002a |
| IL-8 (CXCL8) | 31 | 21 | 0.000a |
| IL-10 | 76 | 56 | 0.016 |
| IL-16 | 370 | 532 | <0.001a |
| IL-17A | 73 | 273 | <0.001a |
| MIF | 808 | 4895 | <0.001a |
| G-CSF | 33 | 127 | <0.001a |
| PDGF-BB | 3288 | 2357 | 0.003a |
| MMP-2 | 37 242 | 89 243 | <0.001a |
| MMP-8 | 9436 | 5072 | <0.001a |
| MMP-12 | 871 | 347 | <0.001a |
Abbreviations: CCL, C-C motif chemokine ligand; COPD, chronic obstructive pulmonary disease; CXCL, C-X-C motif chemokine ligand; G-CSF, granulocyte colony-stimulating factor; IL, interleukin; MIF, macrophage migration inhibitory factor; MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; NSCLC, non small cell lung cancer; PDGF-BB, platelet-derived growth factor subunit B; TARC, thymus and activation regulated cytokine. Concentrations measured in pg ml−1.
a
Statistically significant P-values retained after correction for multiple.